Bio-Rad Buys Sanofi Dx
Executive SummaryBio-Rad Laboratories is buying Sanofi Diagnostics from Sanofi-Synthelabo in order to increase its mass, goegraphical scope, and diversity of product lines. Bio-Rad, which has life sciences and analytical instruments businesses in addition to a clinical diagnostics business, makes a number of assays and it is looking to increase its presence in infectious diseases, where Sanofi is strong. Sanofi makes tests for infectious diseases and is strong in HIV diagnostics. Burt does Bio-Rad have the wherewithall to make this deal work, given the two companies differ in culture and strengths?
You may also be interested in...
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.